Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Raises Full-Year Profit Guidance, Expects Higher Covid-19 Vaccine Sales

05/04/2021 | 07:21am EDT

By Matt Grossman

Pfizer Inc. on Tuesday raised its full-year revenue and earnings guidance, citing a higher estimate of sales of its Covid-19 vaccine.

Pfizer now expects full-year revenue of $70.5 billion to $72.5 billion, compared with previous guidance for revenue of $59.4 billion to $61.4 billion.

The company forecast a full-year adjusted profit of $3.55 a share to $3.65 a share. It had previously said it expected an adjusted profit of $3.10 a share to $3.20 a share.

Pfizer expects its Covid-19 vaccine developed with BioNTech SE to generate revenue of about $26 billion in the year. It had previously guided for revenue of about $15 billion from the shot.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

05-04-21 0721ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 9.35% 183.71 Delayed Quote.125.36%
PFIZER, INC. 1.00% 39.58 Delayed Quote.6.47%
All news about PFIZER, INC.
03:16pMODERNA  : All adults can book COVID vax at select Ontario hot spot pharmacies
AQ
02:11pMODERNA  : U.S. administers 257.3 mln doses of COVID-19 vaccines –CDC
RE
01:48pEU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vac..
DJ
09:27aPFIZER  : EU pens contract for further 1.8 billion Pfizer shots
AQ
06:22aEU sceptical on vaccine waiver, but ready to discuss proposal
RE
04:55aASTRAZENECA  : Sri Lanka approves Pfizer COVID vaccine for emergency use
RE
04:01aWho have provinces pegged to receive COVID-19 vaccines in the coming weeks?
AQ
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07Health Care Up On Cyclical Bias -- Health Care Roundup
DJ
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
RE
More news
Financials (USD)
Sales 2021 69 466 M - -
Net income 2021 17 545 M - -
Net Debt 2021 27 786 M - -
P/E ratio 2021 14,1x
Yield 2021 4,00%
Capitalization 221 B 221 B -
EV / Sales 2021 3,58x
EV / Sales 2022 4,25x
Nbr of Employees 78 500
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Average target price 41,65 $
Last Close Price 39,58 $
Spread / Highest target 33,9%
Spread / Average Target 5,22%
Spread / Lowest Target -9,04%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.6.47%220 784
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539
NOVARTIS AG-4.97%197 775